|
|
||||||||
J Thorac Cardiovasc Surg 1998;116:206-212
© 1998 Mosby, Inc.
Surgery for Adult Cardiovascular Disease |
From the Department of Cardiothoracic Surgery, National Heart and Lung Institute, Imperial College of Science Technology and Medicine, Heart Science Centre, Harefield Hospital, Harefield, Uxbridge, United Kingdom,a and the Vascular Biology Centre, Medical School of Georgia, Augusta, Ga.b
Received for publication Sept. 16, 1997. Revisions requested Nov. 12, 1997; revisions received Dec. 18, 1997. Accepted for publication Feb. 4, 1998. Address for reprints: Magdi H. Yacoub, FRCS, FRCP, DSc, Department of Cardiothoracic Surgery, Harefield Hospital, National Heart and Lung Institute, Heart Science Centre, Harefield, Middlesex UB9 6JH, United Kingdom.
Objective: The activity of the renin-angiotensin system may be important in determining the performance of coronary artery bypass grafts. We have examined the activity of tissue angiotensin-converting enzyme and the effects of angiotensin II in vessels used as bypass grafts.
Methods: Organ bath studies were used to determine the vasoactive effect of angiotensin II. The activity of the angiotensin-converting enzyme was assessed by metabolism of a specific synthetic substrate.
Results: The saphenous vein produced greater maximum responses to angiotensin II than did the internal thoracic artery. This response was not modified by inhibition of nitric oxide synthase, cyclooxygenase, or by an endothelin receptor antagonist in either vessel. Losartan, an AT1 receptor antagonist, inhibited the vasoconstrictor response in both blood vessels. Homogenates of saphenous vein and internal thoracic artery displayed tissue angiotensin-converting enzyme activity, which was inhibited by captopril. Enzyme activity was threefold greater in the vein. Both the contractile response to angiotensin II and the enzyme activity were retained in venous grafts removed up to 20 years after coronary bypass surgery.
Conclusions: These data demonstrate that marked differences exist in angiotensin-converting enzyme activity and AT1 receptor responses in the saphenous vein compared with the internal thoracic artery. These findings may have important implications for the performance of the vein when used as a coronary artery bypass graft and may have clinical implications for the use of angiotensin-converting inhibitors and AT1 receptor antagonists in the prevention and treatment of vein graft disease.
This article has been cited by other articles:
![]() |
H. L. Lazar All Coronary Artery Bypass Graft Surgery Patients Will Benefit From Angiotensin-Converting Enzyme Inhibitors Circulation, January 1, 2008; 117(1): 6 - 8. [Full Text] [PDF] |
||||
![]() |
H. L. Lazar Role of Angiotensin-Converting Enzyme Inhibitors in the Coronary Artery Bypass Patient Ann. Thorac. Surg., March 1, 2005; 79(3): 1081 - 1089. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Arcaro, A. Solini, T. Monauni, A. Cretti, B. Brunato, A. Lechi, R. Fellin, M. Caputo, C. Cocco, E. Bonora, et al. ACE Genotype and Endothelium-Dependent Vasodilation of Conduit Arteries and Forearm Microcirculation in Humans Arterioscler. Thromb. Vasc. Biol., August 1, 2001; 21(8): 1313 - 1319. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nishimoto, S. Takai, Y. Sawada, A. Yuda, K. Kondo, M. Yamada, D. Jin, M. Sakaguchi, K. Asada, S. Sasaki, et al. Chymase-dependent angiotensin II formation in the saphenous vein versus the internal thoracic artery J. Thorac. Cardiovasc. Surg., April 1, 2001; 121(4): 729 - 734. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A.A. Borland, A. H. Chester, S. J. Rooker, J. Wharton, N. Davie, M. Amrani, and M. H. Yacoub Expression and function of angiotensin converting enzyme, chymase, and angiotensin II in the human radial artery and internal thoracic artery Ann. Thorac. Surg., December 1, 2000; 70(6): 2054 - 2063. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Stanke-Labesque, P. Devillier, P. Bedouch, J. L. Cracowski, O. Chavanon, and G. Bessard Angiotensin II-induced contractions in human internal mammary artery: effects of cyclooxygenase and lipoxygenase inhibition Cardiovasc Res, August 1, 2000; 47(2): 376 - 383. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Berry, C. A. Hamilton, M. J. Brosnan, F. G. Magill, G. A. Berg, J. J. V. McMurray, and A. F. Dominiczak Investigation Into the Sources of Superoxide in Human Blood Vessels : Angiotensin II Increases Superoxide Production in Human Internal Mammary Arteries Circulation, May 9, 2000; 101(18): 2206 - 2212. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |